Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
|
|
TELA Bio, Inc. (TELA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/16/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/09/2023 |
8-K
| Investor presentation, Quarterly results |
| 05/11/2023 |
8-K
| Investor presentation, Quarterly results |
| 04/20/2023 |
8-K
| Quarterly results |
| 04/18/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/21/2023 |
8-K
| Investor presentation, Quarterly results |
| 01/10/2023 |
8-K
| Investor presentation |
| 01/09/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/09/2022 |
8-K
| Quarterly results |
| 10/26/2022 |
8-K
| Quarterly results |
| 08/17/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
8-K
| Quarterly results |
| 08/10/2022 |
8-K
| Quarterly results |
| 06/02/2022 |
8-K
| Quarterly results |
| 05/31/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 03/21/2022 |
8-K
| Investor presentation, Quarterly results|
Docs:
|
"TELA Bio, Inc. Consolidated Balance Sheets December 31, 2021 2020 Assets Current assets: Cash and cash equivalents $ 43,931 $ 74,394 Accounts receivable, net 4,234 2,683 Inventory 7,658 3,907 Prepaid expenses and other assets 3,232 2,241 Total current assets 59,055 83,225 Property and equipment, net 1,186 626 Intangible assets, net 2,303 2,607 Total assets $ 62,544 $ 86,458 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 2,414 $ 652 Accrued expenses and other current liabilities 8,161 5,953 Total current liabilities 10,575 6,605 Long-term debt with related party 31,491 30,827 Other long-term liabilities 380 — Total liabilities 42,446 37,432 Stockholders’ equity: Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding —...",
"Advancing Soft Tissue Reconstruction Investor Presentation March 2022" |
|
| 03/03/2022 |
8-K
| Quarterly results |
| 11/10/2021 |
8-K
| Investor presentation, Quarterly results|
Docs:
|
"TELA Bio, Inc. Consolidated Balance Sheets September 30, December 31, 2021 2020 Assets Current assets: Cash and cash equivalents $ 53,636 $ 74,394 Accounts receivable, net 3,573 2,683 Inventory 6,269 3,907 Prepaid expenses and other assets 2,061 2,241 Total current assets 65,539 83,225 Property and equipment, net 891 626 Intangible assets, net 2,379 2,607 Total assets $ 68,809 $ 86,458 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 2,334 $ 652 Accrued expenses and other current liabilities 7,043 5,953 Total current liabilities 9,377 6,605 Long-term debt with related party 31,315 30,827 Other long-term liabilities 388 — Total liabilities 41,080 37,432 Stockholders’ equity: Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and ou...",
"Corporate Slide Deck" |
|
| 11/09/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/01/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/27/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/11/2021 |
8-K
| Quarterly results |
| 06/07/2021 |
8-K
| Quarterly results |
| 05/19/2021 |
8-K
| Quarterly results |
| 05/13/2021 |
8-K
| Quarterly results |
| 05/04/2021 |
8-K
| Quarterly results |
| 04/22/2021 |
8-K
| Quarterly results |
| 03/29/2021 |
8-K
| Quarterly results |
| 03/24/2021 |
8-K
| Quarterly results |
| 01/14/2021 |
8-K
| Quarterly results |
| 12/29/2020 |
8-K
| Entry into a Material Definitive Agreement |
|
|
|